fcmc  (Technical Manufacturing Company)

Journal: Gels

Article Title: Tissue Adhesive, Biocompatible, Antioxidant, and Antibacterial Hydrogels Based on Tannic Acid and Fungal-Derived Carboxymethyl Chitosan for Wound-Dressing Applications

doi: 10.3390/gels9050354

Figure Lengend Snippet: Schematic representation of formation of TA-FCMCS hydrogel.

Article Snippet: Specifically, the XRD patterns of TA-FCMCS hydrogels were recorded using a Bruker AXS D8 advance diffractometer in Bragg–Brentano geometry, which involves a sample mounted on a rotating stage and the use of an X-ray source.

Techniques:

Journal: EBioMedicine

Article Title: Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer

doi: 10.1016/j.ebiom.2016.07.027

Figure Lengend Snippet: A schematic outline of CTC detection using the FCMC system. (A) Assembled FCMC device (top side) and cross-sectional scanning electron microscope image of the microchambers (bottom side). The rectangular area indicates the area used for flatness measurement, the arrow indicates the area used for measurement of roughness and the circle enclosing a white line indicates the area used for measurement of the radius of the microchamber rim. (B) A zoomed side view of the flow channel over the microchamber. The depth, and the top and bottom diameter of each microchamber, and the height of the flow channel are indicated. (C) A zoomed top view of the flow channel. Distances between microchambers are indicated. The orange colored area is coated with BSA. (D) A top view of the flow channel. The size of the flow channels and the microchamber area are indicated. (E) Bright field view of cells trapped as a tight monolayer in a microchamber. (F) Immunostained cells in microchambers. All of the cells are trapped in microchambers. Leukocytes are immunostained with an anti-CD45 antibody and labeled with Alexa fluor 488 dye (green). Blue: Hoechst 33342 (nucleus).

Article Snippet: We also analyzed the CTC count per 1.6 mL of peripheral blood from each of 20 healthy donors in Konica Minolta, Inc. (Tokyo, Japan) using the FCMC system, in order to determine a threshold value for the CTC counts using this system.

Techniques: Microscopy, Labeling

Journal: EBioMedicine

Article Title: Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer

doi: 10.1016/j.ebiom.2016.07.027

Figure Lengend Snippet: Workflow of sample processing and movement of cells in the FCMC device. (A) Workflow of sample processing and CTC detection. (a) Blood sample collection and enrichment using Ficoll-Paque PLUS. (b) The cell suspension is loaded into the FCMC device. The cells form monolayers in the microchambers and are immunostained by using a syringe pump. (c) All microchambers are scanned using a fluorescent microscope. (d) CTC are detected from the fluorescent images. (B) Movement of cells in the FCMC device. (a) The new CM chip, which is made from polystyrene (PS), is cleaned with UV ozone and coated with BSA. (b) The FCMC device is washed with PBS. (c) A cell suspension (68 uL) that is equivalent to 0.4 mL of blood is loaded into one FCMC device. (d) After “Suction for Trapping”, untrapped cells move into downstream microchambers and settle down on the bottom of these microchambers. The blue arrows indicate flow. (e) After “Suction for Monolayer”, overlapped cells are discharged from microchambers and move to the outside of microchambers or to the inside of downstream microchambers. (f) After repetitions of (d) and (e), all cells are trapped in a monolayer. (g), (h), (i) Immunostaining solutions are loaded, incubated and washed.

Article Snippet: We also analyzed the CTC count per 1.6 mL of peripheral blood from each of 20 healthy donors in Konica Minolta, Inc. (Tokyo, Japan) using the FCMC system, in order to determine a threshold value for the CTC counts using this system.

Techniques: Suspension, Microscopy, Immunostaining, Incubation

Journal: EBioMedicine

Article Title: Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer

doi: 10.1016/j.ebiom.2016.07.027

Figure Lengend Snippet: CTC counts in healthy donors detected using the FCMC system. The CTC counts in 1.6 mL blood of 20 healthy donors were analyzed using the FCMC system.

Article Snippet: We also analyzed the CTC count per 1.6 mL of peripheral blood from each of 20 healthy donors in Konica Minolta, Inc. (Tokyo, Japan) using the FCMC system, in order to determine a threshold value for the CTC counts using this system.

Techniques:

Journal: EBioMedicine

Article Title: Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer

doi: 10.1016/j.ebiom.2016.07.027

Figure Lengend Snippet: Patient characteristics and the results of CTC counts. The CTC counts of 22 patients with breast cancer were analyzed using the FCMC system or the CellSearch system. *, the CTC counts of patients numbered 1–5 were analyzed using an FCMC device that had about 15,000 microchambers in the flow channel, and the counts of patients numbered 6–22 were analyzed using an FCMC device that had about 18,000 microchambers. **, CTC counts detected in 1.6 mL blood using the FCMC system are normalized to a value of 7.5 mL. All patients were under treatment of chemotherapy or hormonotherapy. The results of the most recent CT evaluation for disease are listed. Abbreviations: female, F. CT, chemotherapy. HT, hormonotherapy. PR, partial response. SD, stable disease. PD, progressive disease.

Article Snippet: We also analyzed the CTC count per 1.6 mL of peripheral blood from each of 20 healthy donors in Konica Minolta, Inc. (Tokyo, Japan) using the FCMC system, in order to determine a threshold value for the CTC counts using this system.

Techniques:

Journal: EBioMedicine

Article Title: Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer

doi: 10.1016/j.ebiom.2016.07.027

Figure Lengend Snippet: Comparison of the CTC counts detected in patients with breast cancer using the FCMC system and the CellSearch system, and progression free survival in patients in whom CTC were detected or not detected using the FCMC system or the CellSearch system. (A) The CTC counts of twenty-two patients with breast cancer were evaluated. For comparison with the CellSearch system, the results of the FCMC system from 1.6 mL blood were normalized to a value of 7.5 mL. The number of CTC counts detected using the FCMC system was statistically higher than that using the CellSearch system ( p = 0.00037, Wilcoxon signed rank test). (B) Typical immunofluorescence stained CTC images of a patient with breast cancer. CTC was defined as cytokeratin (CK) positive, CD45 negative and Hoechst 33342 (nucleus) positive. Scale bar, 20 μm. (C,D) Kaplan-Meier curves of progression free survival (PFS) in patients in whom CTC were detected (CTC +) or not detected (CTC −) using (C) the FCMC system or (D) the CellSearch system are shown. CTC + is defined as detected CTC counts that are above the threshold level of each system (FCMC, 3 CTC/1.6 mL; CellSearch, 1 CTC/7.5 mL). The log-rank test of PFS showed significant differences according to CTC detection in both systems (FCMC: p = 0.000244, CellSearch: p = 0.0082). The median PFS of CTC + patients (40 days; 95% CI, 0 to N.E., not estimable) and CTC − patients (194 days; 95% CI, 173 to N.E.) as assessed using the FCMC system is shown in (C). The median PFS of CTC + patients (97 days; 95% CI, 0 to 173) and CTC − patients (325 days; 95% CI, 33 to N.E.) as assessed using the CellSearch system is shown in (D). The hazard ratio for PFS was 11.31 (95% confidence interval [CI], 2.245 to 57.0; p = 0.003284) for CTC + patients as compared with CTC − patients using the FCMC system, and was 4.229 (95% CI, 1.31 to 13.66; p = 0.01591) for CTC + patients as compared with CTC − patients using the CellSearch system. Patients remained in the study unless they met a criterion for disease progression.

Article Snippet: We also analyzed the CTC count per 1.6 mL of peripheral blood from each of 20 healthy donors in Konica Minolta, Inc. (Tokyo, Japan) using the FCMC system, in order to determine a threshold value for the CTC counts using this system.

Techniques: Comparison, Immunofluorescence, Staining, Biomarker Discovery